Literature DB >> 2357852

Loss of natural killer activity as an indicator of relapse in acute leukaemia.

J A Tratkiewicz1, J Szer.   

Abstract

A role for naturally occurring cytotoxic cells in immunosurveillance against malignancy has been presumed in several studies. The natural killer activity (NKA) of peripheral blood mononuclear cells was therefore measured at regular intervals in patients with acute leukaemia and expressed specific cytotoxicity. Sixty controls had a median NKA of 33.6% (range 15.4-71). Seventy-three patients with acute lymphoblastic leukaemia (ALL) and acute non-lymphoblastic leukaemia (ANLL) with untreated or relapsed disease had a median activity of 2.4% (range 0-13.4) (P less than 0.001), while 57 patients who had achieved complete remission had a median activity of 22.7% (range 9.5-64.4). In 15 patients, reductions of NKA were seen prior to 16 episodes of relapse. In ten of these (nine with ANLL and one with ALL), 11 relapses were preceded within 10 weeks by drops in NKA to less than 30% of remission levels. The median NKA of the group prior to the drop in activity was 25.5% and the median first low value was 6.0%. Five patients who relapsed after allogeneic bone marrow transplantation had significant, sustained drops in NKA, 5-9 weeks earlier. The median NKA prior to the drop was 25.6% and the median first low value was 8.0%. We therefore conclude that there was a marked reduction in NKA in patients with active acute leukaemia when compared with healthy blood donors and that this activity substantially improved in complete remission. All patients who relapsed had significantly reduced NKA which in some, significantly preceded the time of relapse. These data suggest that the regular assessment of NKA in patients with acute leukaemia may be a useful diagnostic tool.

Entities:  

Mesh:

Year:  1990        PMID: 2357852      PMCID: PMC1535297          DOI: 10.1111/j.1365-2249.1990.tb05241.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  K562--a human erythroleukemic cell line.

Authors:  L C Andersson; K Nilsson; C G Gahmberg
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

Review 2.  Natural cell-mediated immunity.

Authors:  R B Herberman; H T Holden
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity.

Authors:  H D Kay; G D Bonnard; W H West; R B Herberman
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

4.  Characterization of human lymphocyte subpopulations for cytotoxicity against tumor-derived monolayer cultures.

Authors:  T Bakács; P Gergely; S Cornain; E Klein
Journal:  Int J Cancer       Date:  1977-04-15       Impact factor: 7.396

5.  A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice.

Authors:  A Mantovani; W Luini; G Peri; A Vecchi; F Spreafico
Journal:  J Natl Cancer Inst       Date:  1978-11       Impact factor: 13.506

7.  Natural cytotoxicity of adherent cells from human blood: role of the Fc receptor.

Authors:  F A Barada; H D Kay; R Emmons; J S Davis; D A Horwitz
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

8.  Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody.

Authors:  C Ching; C Lopez
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

9.  Natural killer activity in patients with acute myelocytic leukemia.

Authors:  Y Stupp; E Rosenkovitch; G Izak
Journal:  Isr J Med Sci       Date:  1978-12

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  13 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.

Authors:  J K Orleans-Lindsay; L D Barber; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

3.  MicroRNA-29b mediates altered innate immune development in acute leukemia.

Authors:  Bethany L Mundy-Bosse; Steven D Scoville; Li Chen; Kathleen McConnell; Hsiaoyin C Mao; Elshafa H Ahmed; Nicholas Zorko; Sophia Harvey; Jordan Cole; Xiaoli Zhang; Stefan Costinean; Carlo M Croce; Karilyn Larkin; John C Byrd; Sumithira Vasu; William Blum; Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  J Clin Invest       Date:  2016-10-24       Impact factor: 14.808

4.  Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function.

Authors:  Steven D Scoville; Ansel P Nalin; Luxi Chen; Li Chen; Michael H Zhang; Kathleen McConnell; Susana Beceiro Casas; Gabrielle Ernst; Abd Al-Rahman Traboulsi; Naima Hashi; Monica Williams; Xiaoli Zhang; Tiffany Hughes; Anjali Mishra; Don M Benson; Jennifer N Saultz; Jianhua Yu; Aharon G Freud; Michael A Caligiuri; Bethany L Mundy-Bosse
Journal:  Blood       Date:  2018-08-29       Impact factor: 22.113

Review 5.  Natural killer cells and acute myeloid leukemia: promises and challenges.

Authors:  Shayan Rahmani; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Cancer Immunol Immunother       Date:  2022-05-31       Impact factor: 6.630

6.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

7.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.

Authors:  Nathaniel J Buteyn; Ramasamy Santhanam; Giovanna Merchand-Reyes; Rakesh A Murugesan; Gino M Dettorre; John C Byrd; Anasuya Sarkar; Sumithira Vasu; Bethany L Mundy-Bosse; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2020-02-24       Impact factor: 5.422

8.  Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

Authors:  M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 9.  Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.

Authors:  Alissa Martin; Elaine Morgan; Nobuko Hijiya
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

10.  Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiang-Yu Zhao; Xing-Xing Yu; Zheng-Li Xu; Xun-Hong Cao; Ming-Rui Huo; Xiao-Su Zhao; Ying-Jun Chang; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Blood Adv       Date:  2019-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.